Urologist, Clinical Professor, Department of Surgery
University of Alberta, Alberta Urology Institute, Edmonton, AB
Dr Michael Chetner is a member of the Division of Urology and a Clinical Professor in the Department of Surgery, in the Faculty of Medicine and Dentistry at the University of Alberta. He completed his urology residency at the University of Alberta, during which time he completed his Masters in Science in Experimental Surgery focusing on photodynamic therapy in a rat prostate cancer model. He did his “Fellowship” training in Seattle at the Veteran’s Administration Medical Center (VMAC) and at the University of Washington under Dr. M.K. Brawer, Dr Paul H. Lange & Dr Michael E. Mayo in the fields of continent urinary diversion and the diagnosis and management of prostate cancer. He has been a practicing urologist in Edmonton since 1991. His current clinical practice focuses on both benign and malignant prostate disease (Minimally Invasive Surgery) and uro-oncology. His current research activities are focused on clinical trials in BPH and prostate cancer.
He is the past Divisional Director of Urology in the Department of Surgery at the University of Alberta (1995 – 2010). Past Secretary of the Canadian Urological Association ( CUA, 1997-2002), past Executive Committee Member of the CUA (President 2012). Past President of the Alberta Society of Urology (ASU – 1991-1996). Executive Committee Member of the Canadian Uro-Oncology Group (CUOG – 1992-1998), Treasurer of CUOG (1996-1998). Member of the Canadian Council of University Urologic Chairs (CCUUC – 1996-2010, Chair of CCUUC, 2002-2008). Nucleus Member and Test Committee Member, Royal College of Surgeons of Canada (RCSC) on Principles of Surgery (1992-1995), Test Committee and Examination Board in Urology Royal College of Surgeons of Canada (RCSC – 1994-1999). Contributing Editor and Editorial Board Member (reviewer) on multiple national and international Journals and publications.
Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J. 2011 Dec;5(6):416-21
Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14;365(2):107-18.
Fairey AS, Jacobsen NE, Chetner MP, Mador DR, Metcalfe JB, Moore RB, Rourke KF, Todd GT, Venner PM, Voaklander DC, Estey EP. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database. J Urol. 2009 Jul;182(1):85-92; discussion 93.
Moore KN, Valiquette L, Chetner MP, Byrniak S, Herbison GP. Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology. 2008 Dec;72(6):1280-6.
Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, Kuan J, Brock GB, Tanguay S.Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol. 2004 Jul;172(1):58-62.
Gleave ME, Goldenberg, SL, Chin J, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner, MP, Dupont, C., Van Rensselaer, S., The Canadian Uro-Oncology Group Randomized Comparative Study Of 3 Versus 8-Month Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Biochemical And Pathological Effects. J. Urol. 166:500-507, 2001
Chetner, M.P. “Detection and Diagnosis of Prostate Cancer – The Role of PSA” in Abel, M., & Lalani, E.N.: Prostate Cancer: Scientific and Clinical Aspects – Bridging the Gap, Imperial College Press, in press.
Scrimger, R.A., Murtha, A.D., Parliament, M.B., Venner, P.M., Hanson, J., Houle, G., Chetner, M.P. Muscle Invasive Transitional Cell Carcinoma of the Urinary Bladder: A Population Based Study of Patterns of Care and Prognostic Factors. Int. J. Radiation Oncology Biol. Phys. Vol 51, No. 1:23, 2001
Kaufman, D.S., Winter, K.A., Shipley, W.U., Heney, N.M., Chetner, M.P., Southami, L., Zlotecki, R.T., Sause, W.T., True, L.D.The Initial Results in Muscle Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response. The Oncologist and Stem Cells. Oncologist 5(6), 471-6, 2000.
Grover, S.A., Coupal, L., Zowall, H., Rajan, R., Trachtenberg, J., Elhilali, M., Chetner, M.P., Goldenberg, S.L., Prowse, O. Estimating The Clinical Burden of Prostate Cancer: A validated Disease Progression Model. CMAJ. 2000 Apr. 4;162(7): 977-83
Grover, S.A., Coupal, L., Zowall, H., Rajan, R., Trachtenberg, J., Elhilali, M., Chetner, M.P., Prowse, O. The Economic Burden of Prostate Cancer in Canada: Forecasts from the Montreal Prostate Cancer Model. CMAJ. 2000 Apr. 4;162(7): 987-992
Gajewski, J., Chancellor, D.A., Ackman, C.F.D., Appell, R.A., Bennett, J., Binard, J., Boone, T.B., Chetner, M.P., Crewalk, J., Delfalco, A., Foote, J., Green, B., Juma, S., Jung, S.Y., Linsenmeyer, C.A., MacMillan, R., Mayo, M., Roehrborn, C.G., Stone, A., Shenot, P.J., Vazquez, A., Killorin, W., Rivas, D.A. Removal of the UroLume® endoprosthesis: Experience of the North American Study Group for Detrusor Sphincter Dyssynergia Application. J. Urol.,163 (4), March 2000.
Chancellor, D.A., Linsenmeyer, C.A., Ackman, C.F.D., Appell, R.A., Bennett, J., Binard, J., Boone, T.B., Chetner, M.P., Crewalk, J., Delfalco, A., Foote, J., Gajewski, J., Green, B., Juma, S., Jung, S.Y., MacMillan, R., Mayo, M., Roehrborn, C.G., Stone, A., Rivas, D.A., Shenot, P.J., Vazquez, A. Long Term Follow-up (5 years) Of the North American Multi-center UrolumeR Trial for the Treatment of Detrusor External Sphincter Dyssynergia. J. Urol., 161 (5), May 1999.
Morris, B., Browne, G., Chan, P., Chow, V., Nam, R., Paulter, P., Jewett, M., Chetner, M.P., Elhilali, M.: Learning Needs of Canadian Urology Residents – A survey. Can. J. Urol. 6(3); June 1999
Klotz, L., Goldenberg, S.L., Jewitt, M., Barkin, J., Chetner, M.P., Fradet, Y., Chin, J., Laplante, S., and CUOG P92 Study Group: A CUOG Randomized Trial of Neoadjuvant Androgen Ablation Prior To Radical Prostatectomy: 36 Month Post-Treatment PSA Results. Urol., 53 (4), Apr 1999.
Brawer, M.K., Chetner, M.P. “Prostate Biopsy – Preparation and Technique”, in M. Resnick and I. Thompson: Surgery of the Prostate, Churchill and Livingston, 1998.
Brawer, M.K., Chetner, M.P. “Transrectal Ultrasound in Prosate Cancer”, in Walsh, P.C., Gittes, R.F., Perlmutter, A.D., Stamey, T.A., ed.: Campbell’s Urology, 7th Edition, W.B. Saunders Co., 1997.
Chetner, M.P. Urinary Diversion – A Perspective. Ostomy International, Vol. 17, No. 1, 1996.
Brawer, M.K., Chetner, M.P. “Detection of Early Prostate Cancer – PSA”, in Peeling, W.B., ed.: Questions and Uncertainties in Prostate Cancer, 1st Edition, Blackwell Science Ltd., 1996.
Chetner, M.P. Uro-Politics – Assessing Klein’s Take on Health Care Reform, Urology Times of Canada, Vol. 3, No. 1, Feb. 1995.
Moore, K.N., Chetner, M.P., Metcalfe, J.B., Griffiths, D.J.: Peri-urethral Implantation of GAX-Collagen (Contigen®) in Women with Type I or III Stress Incontinence: Quantitative Outcome Measures. Br. J. Urol., 75:359, 1995.
Nickel, C., Chetner, M.P., Mahoney, J., Anderson, P., Saad, F., Benard, F., Piercy, G.B. Prostatitis: A State of the Art Clinical Update – Issue #3: Treatment. Science and Medicine Canada (Publisher), 1994.
Nickel, C., Chetner, M.P., Mahoney, J., Anderson, P., Saad, F., Benard, F., Piercy, G.B. Prostatitis: A State of the Art Clinical Update – Issue #2: Diagnosis. Science and Medicine Canada (Publisher), 1994.
Nickel, C., Chetner, M.P., Mahoney, J., Anderson, P., Saad, F., Benard, F., Piercy, G.B. Prostatitis: A State of the Art Clinical Update – Issue #1: Epidemilogy and Pathogenesis. Science and Medicine Canada (Publisher), 1994.
Ellis W.J., Chetner M.P., Preston S.D., Brawer M.K. Diagnosis of Prostatic Carcinoma: The Yield of Serum PSA, DRE and TRUS. J. Urol., No. 5, Vol. 152:1520, Nov. 1994.